Global X China Biotech ETF (HKG:9820)

Assets	674.13M
Expense Ratio	0.68%
PE Ratio	27.54
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	-4.22%

Volume	400
Open	9.76
Previous Close	9.80
Day's Range	9.76 - 9.77
52-Week Low	7.30
52-Week High	10.66
Beta	n/a
Holdings	46
Inception Date	Jul 25, 2019

About 9820

2820.HK was created on 2019-07-25 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Global X China Biotech ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Underlying Index.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9820
• Provider: Global X
• Index Tracked: Solactive China Biotech Index

Performance

9820 had a total return of -4.22% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.80%.

Top 10 Holdings

85.51% of assets

Name	Symbol	Weight
Cash	n/a	24.62%
WuXi Biologics (Cayman) Inc.	2269	11.10%
BeOne Medicines AG	ONC	9.74%
Innovent Biologics, Inc.	1801	9.07%
WuXi AppTec Co., Ltd.	603259	8.76%
Akeso, Inc.	9926	5.78%
Sino Biopharmaceutical Limited	1177	4.46%
Jiangsu Hengrui Pharmaceuticals Co.,Ltd	600276	4.39%
Genscript Biotech Corporation	1548	3.85%
Hansoh Pharmaceutical Group Company Limited	3692	3.75%

Data Sources: S&P Global Market Intelligence, Twelve Data, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error